Tag

Immunotherapy

All articles tagged with #immunotherapy

business3 days ago•2 min saved

Gilead buys Arcellx for $7.8B to bolster CAR-T push against Carvykti

Gilead agreed to acquire Arcellx for about $7.8 billion in cash to take full control of the BCMA-targeted CAR-T therapy anito-cel as FDA review proceeds, paying $115 a share—a 68% premium to Arcellx's 30-day VWAP with a $5-per-share contingent payout if global sales reach $6 billion by 2029; the deal aims to sharpen Gilead's cell-therapy portfolio and compete with J&J/Legend's Carvykti, with analysts noting anito-cel's safety profile and potential to restore momentum for Gilead's Kite unit.

via Fierce Biotech|

#biotech #business #car-t

health6 days ago•2 min saved

Morning immunotherapy timing under fire as data questioned

A Nature Medicine study claiming that administering lung cancer immunotherapy in the morning dramatically reduces progression risk versus afternoon dosing is under fire after scientists flag data inconsistencies, with the journal now launching an investigation.

via statnews.com|

#cancer #data-concerns #dosing-timing

science9 days ago•67 min saved

Tailored mRNA vaccines spark durable T cell immunity in adjuvant TNBC

A phase study in 14 women with adjuvant-treated triple-negative breast cancer shows individualized neoantigen mRNA–LPX vaccines encoding up to 20 mutations elicit robust, multi-epitope CD4+/CD8+ T cell responses that persist for years and correlate with relapse-free outcomes in most patients (up to ~6 years). Vaccinated T cells differentiate into cytotoxic, late-stage effector and stem-like memory (TSCM) phenotypes, with durable clonal lineages detected long after vaccination. Three relapses occurred due to weak responses, MHC I loss, or a genetically distinct recurrent tumor. The findings demonstrate the feasibility of on-demand personalized RNA vaccines and provide insights into immune escape and memory formation to guide future immunotherapy strategies.

via Nature|

#immunotherapy #mrna-vaccine #neoantigen

health21 days ago•7 min saved

Sunrise advantage: morning immunotherapy linked to longer survival in lung cancer

A randomized study in 210 patients with non-small-cell lung cancer found that receiving the first immunotherapy dose before 3 p.m. significantly improved outcomes compared with later dosing: about 11.3 months progression-free survival versus 5.7 months and roughly 45% alive versus 15% at follow-up, with morning treatment also showing more cancer-killing T cells. Experts caution that replication is needed, though a confirmatory trial is underway; the work was published in Nature Medicine.

via cnn.com|

#cancer #circadian-rhythm #health

health-and-medicine27 days ago•6 min saved

CD27 boost could unlock long-lasting cancer vaccine immunity

A 20-year-old breast cancer vaccine trial shows all participants are still alive decades later, suggesting durable immune memory. Researchers found persistent CD27-marked CD4+ T cells can recognize the cancer, hinting that CD27 could make cancer vaccines more effective. In mice, combining the vaccine with a CD27-activating antibody nearly doubled tumor elimination (about 40% complete responses vs 6% with vaccine alone); adding extra support for CD8+ T cells pushed tumor rejection to ~90%. These findings imply CD27 could be a key addition to cancer vaccines and compatible with existing therapies.

via ScienceDaily|

#cancer-vaccine #cd27 #cd4-t-cells

science27 days ago•7 min saved

Bacteria-Derived Toxin Halts Colorectal Cancer Growth While Sparing Healthy Tissue

Researchers report that MakA, a toxin from Vibrio cholerae, when delivered systemically, slows colorectal tumor growth in mice by increasing tumor cell death and reshaping the tumor's immune environment, with no observable harm to healthy tissue or organs, suggesting a tumor-targeted anti-cancer strategy that requires further clinical study.

via SciTechDaily|

#bacterial-toxin #cancer-research #colorectal-cancer

health29 days ago•11 min saved

Fecal Transplants Boost Immunotherapy Responses and Cut Side Effects in Cancer Trials

Two Nature Medicine studies show that fecal microbiota transplantation (FMT) capsules can both reduce immunotherapy-related toxicity in kidney cancer and improve response rates in lung cancer and melanoma—80% of lung cancer patients and 75% of melanoma patients responded to immunotherapy after FMT (significantly higher than immunotherapy alone) in multicenter Phase II trials using LND101 capsules.

via News-Medical|

#fecal-microbiota-transplantation #health #immunotherapy

health1 month ago•86 min saved

Healthy-donor fecal transplants boost frontline immunotherapy responses in NSCLC and melanoma

In the phase 2 FMT-LUMINate trial, healthy-donor fecal microbiota transplantation given before first-line anti-PD-1 therapy in NSCLC and anti-PD-1 plus anti-CTLA-4 in melanoma yielded high objective response rates (80% in NSCLC; 75% in melanoma) and was deemed safe overall, with no grade 3+ adverse events in NSCLC. Post-FMT microbiome shifts correlated with responses, including the loss of certain deleterious bacteria (e.g., Enterocloster and Clostridium species). Donor source did not predict efficacy, suggesting that remodeling the gut microbiome—specifically eliminating harmful taxa—drives the benefit. Preclinical mouse data supported this mechanism, showing that reintroducing the lost taxa abrogated the anti-tumor effects of immunotherapy. These findings support FMT as a strategy to overcome resistance to checkpoint inhibitors in NSCLC and melanoma.

via Nature|

#fecal-microbiota-transplantation #health #immunotherapy

health1 month ago•6 min saved

Global Expert Alliance Sets Course to Accelerate Therapeutic Cancer Vaccines

More than 50 leading cancer vaccine researchers convene a two-day global think tank—organized by the Cancer Vaccine Coalition and AACR—to align priorities and accelerate development and access to therapeutic cancer vaccines through practical strategies, AI-driven antigen prediction, and coordinated funding and regulatory pathways, with trials across glioblastoma, melanoma, pancreatic, breast, ovarian and liver cancers and support from HSBC Innovation Banking, Northwest Biotherapeutics, Pfizer, and Anixa Biosciences.

via PR Newswire|

#cancer-research #cancer-vaccines #clinical-trials

science1 month ago•7 min saved

Decades-Old Breast Cancer Vaccine Triggers Durable Immune Memory, New Boosting Approach Emerges

Researchers studied survivors from a decades-old breast cancer vaccine trial and found they retain powerful CD27+ immune memory years later. In mice, combining a CD27-activating antibody with a HER2-targeting vaccine dramatically increased tumor rejection, largely via CD4+ T cells and, with additional CD8+ T-cell support, boosted efficacy to near 90%. The findings suggest CD4+ T cells can drive lasting anti-tumor immunity and that a single CD27 boost alongside vaccines could enhance cancer immunotherapies in humans.

via SciTechDaily|

#cancer-vaccine #cd27 #cd4-t-cells

health1 month ago•8 min saved

Personalized Melanoma Vaccine Shows Strong, Lasting Benefit with Immunotherapy

Moderna and Merck report promising results for a patient-tailored mRNA cancer vaccine paired with Keytruda in high-risk melanoma. The vaccine, designed from a patient’s tumor mutations (neoantigens), reduced recurrence or death by 49% versus immunotherapy alone and demonstrated durable immune memory over five years, signaling a potential breakthrough for personalized cancer vaccines and future skin-cancer prevention.

via ZME Science|

#cancer-vaccine #health #immunotherapy

science1 month ago•41 min saved

Twenty Years of Cancer Advances Raise U.S. Five-Year Survival to 70%

A 75th American Cancer Society Cancer Statistics report shows the U.S. five-year cancer survival rate has risen to about 70% (7‑in‑10) thanks to earlier detection and new treatments like immune checkpoint therapy and CAR‑T cell therapy. Survival has improved across cancers (breast 92%, melanoma 95%, prostate 98%), with leukemia and non‑Hodgkin lymphoma up ~20% and 18% and pancreatic and liver cancers also rising (to 13% and 22%). Myeloma and lung cancer survival have climbed to 62% and 15–28%, while late-stage survival now averages 35% (up from 17%). The death rate has fallen about 34% since 1991, saving roughly 4.8 million lives by 2023 — achievements driven by diagnosis, screening, and innovative therapies rather than a cure.

via Good News Network|

#cancer-research #cancer-survival #car-t

science1 month ago•5 min saved

Notch Timing Unlocks Lab-Grown Helper and Killer T Cells for Off-the-Shelf Immunotherapy

UBC researchers show that precisely tuning the duration and intensity of Notch signaling in stem cells can reliably steer them to become helper or killer T cells, enabling scalable, off-the-shelf immunotherapies for cancer and other diseases. This overcomes a long-standing bottleneck by producing both T cell types from renewable sources, potentially reducing manufacturing costs and time.

via Indian Defence Review|

#immunotherapy #notch-signaling #off-the-shelf

health1 month ago•4 min saved

Personalized mRNA melanoma vaccine trims five-year recurrence risk by almost 50%, Moderna and Merck report

In a Phase 2 trial of 157 high‑risk stage 3/4 melanoma patients, Moderna and Merck’s personalized mRNA vaccine (mRNA-4157) plus Keytruda reduced recurrence or death at five years by about 49% versus Keytruda alone. Earlier two- and three-year data showed similar risk reductions (44% and 49%). Safety was similar between groups, with fatigue, injection-site pain, and chills most common. Full data aren’t yet published; a Phase 3 trial is underway and more data from this program are expected.

via Ars Technica|

#cancer-vaccine #health #immunotherapy

health1 month ago•18 min saved

Personalized mRNA therapy shows early promise against melanoma in trial

An experimental, tumor-genome–targeted mRNA therapy developed by Moderna and Merck, when combined with Keytruda, reduced the risk of melanoma recurrence or death in an ongoing clinical trial, signaling a potential new precision approach for aggressive skin cancer.

via The Washington Post|

#cancer #clinical-trials #health